Sudarshan Sharma

4.7k total citations · 3 hit papers
55 papers, 2.1k citations indexed

About

Sudarshan Sharma is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Sudarshan Sharma has authored 55 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Obstetrics and Gynecology, 15 papers in Reproductive Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Sudarshan Sharma's work include Endometrial and Cervical Cancer Treatments (16 papers), Ovarian cancer diagnosis and treatment (12 papers) and Endometriosis Research and Treatment (5 papers). Sudarshan Sharma is often cited by papers focused on Endometrial and Cervical Cancer Treatments (16 papers), Ovarian cancer diagnosis and treatment (12 papers) and Endometriosis Research and Treatment (5 papers). Sudarshan Sharma collaborates with scholars based in United States, India and Canada. Sudarshan Sharma's co-authors include Michael L. Pearl, Scott M. Eisenkop, Nick M. Spirtos, John B. Schlaerth, Joan L. Walker, Richard R. Barakat, Robert S. Mannel, Gregory Spiegel, Marion Piedmonte and Marion R. Piedmonte and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Sudarshan Sharma

48 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2

2009 904 citations Joan L. Walker, Marion Piedmonte et al. Journal of Clinical Oncology profile →
Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study

2012 522 citations Joan L. Walker, Marion R. Piedmonte et al. Journal of Clinical Oncology profile →
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

2020 224 citations Dmitriy Zamarin, Robert A. Burger et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Sudarshan Sharma

Since Specialization

Citations

This map shows the geographic impact of Sudarshan Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudarshan Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudarshan Sharma more than expected).

Fields of papers citing papers by Sudarshan Sharma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sudarshan Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudarshan Sharma. The network helps show where Sudarshan Sharma may publish in the future.

Co-authorship network of co-authors of Sudarshan Sharma

This figure shows the co-authorship network connecting the top 25 collaborators of Sudarshan Sharma. A scholar is included among the top collaborators of Sudarshan Sharma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sudarshan Sharma. Sudarshan Sharma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up 2025 ·International Journal of Gynecological Cancer ·Sudarshan Sharma, Gabriel Lindahl, Lisa M. Landrum, (unknown), Lucy Gilbert, Sarah Gill, (unknown), Kari L. Ring, Nejat Özgül, Bhavana Pothuri, George Fountzilas, (unknown), Evelyn Fleming, Nicole Nevadunsky, Iwona Podzielinski, Kathryn P. Pennington, Qin Shen, Oren Meyers, Matthew A. Powell, Mansoor Raza Mirza	0
2	Cognitive Sensing for Energy-Efficient Edge Intelligence 2024 ·Minah Lee, Sudarshan Sharma, (unknown), (unknown), (unknown), Saibal Mukhopadhyay	2
3	AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. 2024 ·Journal of Clinical Oncology ·Katherine C. Fuh, (unknown), Thomas Reid, Ugo De Giorgi, (unknown), Rebecca Bowen, Devin Miller, Christof Vulsteke, Sudarshan Sharma, Anita Chudecka-Głaz, Joyce F. Liu, Lauriane Eberst, Robert Neff, Peter Lim, David A. Iglesias, (unknown), Tashanna Myers, Antonio González-Martı́n, (unknown)	4
4	Measurement of Aging Effect on an Analog Computing-In-Memory Macro in 28nm CMOS 2024 ·Wei‐Chun Wang, (unknown), Sudarshan Sharma, Minah Lee, Saibal Mukhopadhyay	1
5	ChirpNet: Noise-Resilient Sequential Chirp Based Radar Processing for Object Detection 2024 ·Sudarshan Sharma, (unknown), Saibal Mukhopadhyay	0
6	38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial 2024 ·ESMO Open ·Mansoor Raza Mirza, (unknown), (unknown), Destin Black, (unknown), (unknown), (unknown), (unknown), Antonella Savarese, Robert W. Holloway, (unknown), (unknown), Ingrid Boere, Sudarshan Sharma, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	6
7	Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial 2024 ·Gynecologic Oncology ·(unknown), Sharad Ghamande, Lars Hanker, Destin Black, (unknown), Lucy Gilbert, Ana Oaknin, Angeles Alvarez Secord, Antonella Savarese, Robert G. Holloway, Rebecca Kristeleit, Joseph Buscema, Ingrid Boere, Sudarshan Sharma, Christine Gennigens, Prafull Ghatage, (unknown), Shadi Stevens, (unknown), Matthew A. Powell	11
8	The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study 2024 ·Gynecologic Oncology ·Paulette Mhawech‐Fauceglia, Denis M. McCarthy, Akiko Tonooka, Giovanni Scambia, Yolanda García García, Pavel Dundr, Anne M. Mills, Kathleen N. Moore, Sakiko Sanada, Leslie Bradford, G Stella, Michael A. Bookman, Sudarshan Sharma, Frédèric Selle, Luciana Molinero, (unknown), Victor K. Khor, Charles N. Landen, Yvonne G. Lin	2
9	Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial 2024 ·Gynecologic Oncology ·Matthew A. Powell, Annika Auranen, Lyndsay Willmott, Lucy Gilbert, Destin Black, David Cibula, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars Hanker, Ashley Stuckey, Ingrid Boere, (unknown), Mark S. Shahin, Bhavana Pothuri, Brian M. Slomovitz, Matthew J. Grimshaw, Shadi Stevens, Robert Coleman, (unknown)	5
10	740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial 2023 ·Annals of Oncology ·Mansoor Raza Mirza, Sudarshan Sharma, Jørn Herrstedt, Mark S. Shahin, David Cibula, (unknown), Francesco Raspagliesi, Joseph Buscema, Lars Hanker, Robert L. Coleman, Ingrid Boere, Kami Wolfe Schneider, Lucy Gilbert, Brian M. Slomovitz, Michael Teneriello, Matthew A. Powell, (unknown), (unknown), Kari L. Ring, Ashley Stuckey	20
11	Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11) 2023 ·Gynecologic Oncology ·Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novàk, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars Hanker, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Sarah Gill, Bradley J. Monk, Zangdong He, Shadi Stevens, Robert L. Coleman, Matthew A. Powell	2
12	A High Performance Computing Architecture for Real-Time Digital Emulation of RF Interactions 2023 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sudarshan Sharma, Xiangyu Mao, (unknown), (unknown), Daehyun Kim, (unknown), (unknown), Santosh Pande, Tushar Krishna, Justin Romberg, Madhavan Swaminathan, Saibal Mukhopadhyay	0
13	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study breakdown → 2020 ·Journal of Clinical Oncology ·Dmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes, Michael D. Feldman, Oliver Zivanovic, Camille C. Gunderson, Emily Ko, Cara Mathews, Sudarshan Sharma, Andrea R. Hagemann, Samir N. Khleif, Carol Aghajanian	224
14	Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study breakdown → 2012 ·Journal of Clinical Oncology ·Joan L. Walker, Marion R. Piedmonte, Nick M. Spirtos, Scott M. Eisenkop, John B. Schlaerth, Robert S. Mannel, Richard R. Barakat, Michael L. Pearl, Sudarshan Sharma	522
15	Survival of Dispersed Orphaned Cubs of Tiger ( Panthera tigris tigris ) in Fragmented Habitat of Ranthambhore Tiger Reserve in India 2011 ·Indian Forester ·Randeep Singh, Parag Nigam, Surendra Prakash Goyal, (unknown), Sudarshan Sharma, (unknown)	9
16	Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2 2010 ·Obstetrical & Gynecological Survey ·Joan L. Walker, Marion Piedmonte, Nick M. Spirtos, Scott M. Eisenkop, John B. Schlaerth, Robert S. Mannel, Gregory Spiegel, Richard R. Barakat, Michael L. Pearl, Sudarshan Sharma	1
17	Papillary cystadenocarcinoma of submandibular salivary gland: A rare case report 2010 ·Journal of Cancer Research and Therapeutics ·Kavita Mardi, Sudarshan Sharma, Neelam Gupta	9
18	Cytomorphological features of cell carcinoma: A report of two cases with review of literature 2010 ·Journal of Cytology ·Kavita Mardi, (unknown), Sudarshan Sharma, (unknown)	2
19	Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2 breakdown → 2009 ·Journal of Clinical Oncology ·Joan L. Walker, Marion Piedmonte, Nick M. Spirtos, Scott M. Eisenkop, John B. Schlaerth, Robert S. Mannel, Gregory Spiegel, Richard R. Barakat, Michael L. Pearl, Sudarshan Sharma	904
20	Iodine-125 interstitial implants as salvage therapy for recurrent gynecologic malignancies 1991 ·Cancer ·Sudarshan Sharma, John H. Isaacs, (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact